Hepatitis/MASH

Phase 3 study results show high efficacy and improved renal and bone safety parameters with tenofovir alafenamide regimen.

The FDA has given priority review status to a new drug application for Gilead Sciences' sofosbuvir and velpatasvir as a treatment for chronic genotype 1-6 hepatitis C virus infection.

Sofosbuvir and velpastavir combination being evaluated for hepatitis C genotypes 1-6.

Targeted intervention programs could offer significant benefits in HCV prevention.

Major drug companies are starting to make cheap versions of blockbuster hepatitis C drugs available to people in poor and many middle-income nations.

A middle-aged man experienced complete remission of type 2 diabetes after cure of chronic hepatitis C virus.

Most read HCV articles of the year.

Human pegivirus-2 found only in patients with hepatitis C.

Dr. Raymond Schinazi under fire over HCV drug costs.

Study is the first to demonstrate a strong association between HCV and PD.

From the bright lights of Broadway to the darkness of hepatitis C infection, effective new drugs help patient start life anew.

An estimated 500,000 incarcerated people in the US are currently infected with hepatitis C.

Urban caregivers on the front lines of fighting HCV.

Use of these hepatoprotective agents may reduce the risk of liver damage caused by ingredients in Technivie and Viekira Pak.

Research may offer hope for hepatitis C patients with liver disease.

An overview of Daklinza (daclatasvir) for pharmacists.

Panel suggests different regimens for different hepatitis C patient groups.

Hope on the horizon for patients with liver damage.

Researchers seek a better understanding of the mechanism behind hepatocellular carcinoma.

Risk for illness and death greater due to socioeconomic status of patients with hepatitis C.

Gilead alleged to have priced and marketed Sovaldi to maximize revenue without regard to consequences for patients.

Statins show promise to reduce liver disease incidence in coinfected patients.

Traveling a longer distance to a medical center was not associated with spending more time on a waiting list.

Liver conserving treatments are sorely needed.